Pol Specenier

TL;DR: The clinically meaningful prolongation of overall survival and favourable safety profile of pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma support the further evaluation of p embrolizUMab as a monotherapy and as part of combination therapy in earlier stages of disease.

TL;DR: A recent European randomized trial showed that adding cetuximab, the first clinically available EGFR-directed monoclonal antibody, to a standard chemotherapy regimen (platinum/5-fluorouracil) leads to an important survival benefit and this, with support of an additional smaller study in the US, has changed practice.

TL;DR: Galunisertib + lomustine failed to demonstrate improved OS relative to placebo + lmustine, and patients treated with galun isertib alone had fewer drug-related grade 3/4 adverse events compared with lomUSTine-treated patients.

TL;DR: An update of the most recent data on promising biological prognostic and/or predictive markers, including microsatellite instability, epidermal growth factor receptor, KRAS, BRAF, CpG island methylator phenotype, cytotoxic T lymphocytes, forkhead box P3-positive T cells, receptor for hyaluronic acid-mediated motility, phosphatase and tensin homolog, and T-cell originated protein kinase, in patients with CRC is provided.

TL;DR: It is essential that all clinicians are aware of diabetic ketoacidosis as a rare and life-threatening side effect of immunotherapy.